I am not overwhelmed but am encouraged by the news. Seeing stronger effects in patients treated in second period (placebo then DMX-200) vs vice-versa is consistent with a legacy effects in this crossover design (I.e the good effects of DMX-200 taking longer than expected to wash out). The risk-reward profile here, especially given potential REMAP-CAP upside with continued GWAS hits near CCR2, continues to look favorable to me. Of course I would have welcomed partnership news but this is a decent step.
I am not overwhelmed but am encouraged by the news. Seeing...
-
- There are more pages in this discussion • 166 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add DXB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
54.5¢ |
Change
0.015(2.83%) |
Mkt cap ! $299.6M | |||
| Open | High | Low | Value | Volume |
| 53.0¢ | 54.5¢ | 52.0¢ | $905.8K | 1.698M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 8606 | 53.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 54.5¢ | 72714 | 5 |
View Market Depth
| Last trade - 16.10pm 26/06/2024 (20 minute delay) ? |
| DXB (ASX) Chart |